Did STERIS’ (STE) Record Chemistries Bet and Dividend Hike Just Recast Its Earnings Narrative?

STERIS plc (STE) recently reported strong Q1 fiscal 2027 results, including increased sales and earnings, a reaffirmed full-year outlook, and its 21st consecutive annual dividend increase. The company also announced a significant US$600 million investment in a new chemistries Center of Excellence in North Carolina. This strategic move reinforces STERIS's focus on recurring, compliance-driven revenue streams in infection prevention, though investors should still consider risks like hospital budget pressures and rising input costs.